

jc929 U.S. PTO
10/05/00

Please type a plus sign (+) inside this box

10-10-00

Attorney Docket P1776R2
PATENT


A/Seyc
JC929 U.S. PTO
10/05/00
JC929 U.S. PTO
09/684458

CERTIFICATION UNDER 37 CFR 1.10

EL142012682US: Express Mail Number

October 5, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Box PATENT APPLICATION, Director of Patents and Trademarks, Washington, D.C. 20231.


Glory L. Tabuena

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Director of Patents and Trademarks
Washington, DC 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Mary E. Gerritsen, San Mateo, California
Audrey Goddard, San Francisco, California
J. Christopher Grimaldi, San Francisco, California
Fuad Mehraban, Trumbull, Connecticut

Title: NOVEL POLYPEPTIDES, THEIR NUCLEIC ACIDS, AND METHODS FOR THEIR USE IN
ANGIOGENESIS AND VASCULARIZATION

1. Type of Application

This application is for an original, non-provisional application.

This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by reference.

This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number __, filed __, the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)

(Non-provisional)

164 pages of specification
13 pages of claims
1 page(s) of abstract
0 sheet(s) of drawings
[] formal [] informal

#81700

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

An executed declaration of the inventor(s) [] is enclosed [X] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.

(for cont./div.)

The prior application is assigned of record to Genentech, Inc.

5. Amendments *(for continuation and divisional applications)*

Cancel in this application original claims ___ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

Amend the specification by inserting before the first line the sentence:

This is a

non-provisional application
 continuation
 divisional
 continuation-in-part

of co-pending application(s)

Serial No. ___ filed on ___, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --
 International Application ___ filed on ___ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

P1776R2

X provisional application Nos. 60/158,587 and 60/162,611 filed October 7, 1999 and October 28, 1999, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
Total Claims	112	- 20 =	92	X \$18.00	\$710.00
Independent Claims	42	- 3 =	39	X \$80.00	\$3,042.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$5,486.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$5,486.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

9. Additional Papers Enclosed

- Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- A new Power of Attorney or authorization of agent.
- Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

— A petition, fee and/or response has been filed to extend the term in the pending prior application until

— A copy of the petition for extension of time in the **prior** application is attached.

#81700


P1776R2

11. Correspondence Address:

Address all future communications to:

GENENTECH, INC.
Attn: Timothy R. Schwartz, Ph.D.
1 DNA Way
South San Francisco, California 94080-4990
(650) 225-7467

Respectfully submitted,
GENENTECH, INC.

By: 
Timothy R. Schwartz, Ph.D.

Reg. No. 32,171

Date: October 5, 2000

1 DNA Way
South San Francisco, CA 94080-4990
Phone: (650) 225-7467
Fax: (650) 952-9881

#81700